Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations

International Journal of Antimicrobial Agents

Volumn 46, Issue 1, 2015, Pages 21-27

  Roger, Claire ^a,b   Nucci, Bastian ^a   Molinari, Nicolas ^c   Bastide, Sophie ^a   Saissi, Gilbert ^a   Pradel, Gael ^a,d   Barbar, Saber ^a   Aubert, Clément ^a   Lloret, Sophie ^a   Elotmani, Loubna ^a   Polge, Anne ^a   Lefrant, Jean Yves ^a,b   Roberts, Jason A ^e   Muller, Laurent ^a,b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b University of Montpellier 1   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d Service de Réanimation   (France)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Aminoglycoside; ICU; Peak plasma concentration

Indexed keywords

AMIKACIN; GENTAMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ADULT; ARTICLE; BODY HEIGHT; CANDIDA ALBICANS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SEPSIS; SERRATIA MARCESCENS; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION; AGED; BACTERIAL INFECTIONS; CHEMISTRY; COHORT ANALYSIS; CRITICAL ILLNESS; INTRAABDOMINAL INFECTIONS; PLASMA; PNEUMONIA, BACTERIAL; URINARY TRACT INFECTIONS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; GENTAMICINS; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; PLASMA; PNEUMONIA, BACTERIAL; URINARY TRACT INFECTIONS;

EID: 84934938944     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.02.009     Document Type: Article

References (30)

1. Leone M, Bourgoin A, Cambon S., Dubuc M, Albanèse J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003; 31:462-7.
2. Kumar A, Roberts D, Wood K.E., Light B., Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
3. Dellinger RP, Levy MM, Rhodes A, Annane D., Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
4. Brunkhorst FM, Oppert M, Marx G., Bloos F, Ludewig K, Putensen C., et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012; 307:2390-9.
5. Kumar A, Zarychanski R, Light B., Parrillo J, Maki D, Simon D., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38:1773-85.
6. Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2007; 13:592-7.
7. Zaragoza R, Artero A, Camarena J.J., Sancho S., González R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003; 9:412-8.
8. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia. J Infect Dis 1984; 149:443-8.
9. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-9.
10. Deziel-Evans LM, Murphy JE, Job ML Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986; 5:319-24.
11. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30: 134-44.
12. Mouton JW, Dudley MN, Cars O, Derendorf H., Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55:601-7.
13. Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011; 55:2528-31.
14. AFSSAPF. Bon usage des aminosides administrés par voie injectable: gen-tamicine, tobramycine, nétilmicine, amikacine-Mise au point. AFSSAPF; 2011, http://ansm.sante.fr/Mediatheque/Publications/Recommandations-Medicaments (accessed 12 March 2015).
15. de Montmollin E, Bouadma L, Gault N., Mourvillier B, Mariotte E, Chemam S., et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 2014; 40:998-1005.
16. Gálvez R, Luengo C, Cornejo R., Kosche J, Romero C, Tobar E., et al. Higherthan recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. IntJ Antimicrob Agents 2011; 38:146-51.
17. Taccone FS, Laterre PF, Spapen H, Dugernier T., Delattre I, Layeux B, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14:R53.
18. Marik PE, Havlik I, Monteagudo F.S., Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once-versus twice-daily dosing regimens. J Antimicrob Chemother 1991; 27:81-9.
19. ReaR S, Capitano B, Bies R., Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30:674-81.
20. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-51 (quiz 859).
21. Taccone FS, Laterre PF, Dugernier T, Spapen H., Delattre I, Wittebole X, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14:R126.
22. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-63.
23. Vincent JL, de Mendonca A, Cantraine F, Moreno R., Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on'sepsis-related problems' of the European Society of Intensive Care Medicine. Crit Care Med 1998; 26:1793-800.
24. Mehta RL, Kellum JA, Shah S.V., Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
25. Constantin JM, Leone M, Jaber S., Allaouchiche B, Orban JC, Cannesson M, et al. Activity and the available human resources working in 66 French Southern intensive care units. Ann Fr Anesth Reanim 2010; 29:512-7 [in French].
26. Lefrant JY, Muller L, Raillard A., Jung B, Beaudroit L, Favier L., et al. Reduction of the severe sepsis or septic shock associated mortality by reinforcement of the recommendations bundle: a multicenter study. Ann Fr Anesth Reanim 2010; 29:621-8.
27. Vincent JL, Sakr Y, Sprung C.L., Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis occurrence in acutely Ill patients investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34:344-53.
28. Blackburn LM, Tverdek FP, Hernandez M, Bruno JJ. First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients. Int J Antimicrob Agents 2015; 45:46-53.
29. Leone M, Ragonnet B, Alonso S., Allaouchiche B, Constantin JM, Jaber S, et al. Variable compliance with clinical practice guidelines identified in a 1-day audit at 66 French adult intensive care units. Crit Care Med 2012; 40:3189-95.
30. Cabana MD, Rand CS, Powe N.R., Wu AW, Wilson MH, Abboud PA, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282:1458-65.